Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Veteran drug development leader brings decades of expertise in advancing programs from discovery to clinical stage BOSTON, November 11, 2025 BUSINESS WIRE Odyssey Therapeutics, Inc. , a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the appointment of Dennis Dean, Ph.D., as Executive Vice President and Head of Non-Clinical Development. In this role, Dr. Dean will lead all preclinical research and development activities that support the progression of Odyssey's drug candidates from discovery to clinical trials, including oversight of toxicology, drug metabolism and pharmacokinetics (DMPK), chemistry, manufacturing and controls (CMC), and program management. Dr. Dean will work closely with Discovery Research, Research Operations and Clinical Development to ensure Odyssey's non-clinical programs are scie
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $564.00 price target on by analysts at Morgan Stanley.MarketBeat
- Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]Yahoo! Finance
- Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) [Yahoo! Finance]Yahoo! Finance
- Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/3/25 - Beat
VRTX
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- VRTX's page on the SEC website